Teva Exits Astellas Patent Suit Over Cancer Drug

Law360, New York (March 17, 2011, 12:12 PM EDT) -- Astellas Pharma Inc. unit OSI Pharmaceuticals Inc., Genentech Inc. and Pfizer Inc. settled their infringement suit over generic versions of the cancer treatment Tarceva with Teva Pharmaceuticals USA Inc. in Delaware on Tuesday, leaving Mylan Pharmaceuticals Inc. as the sole defendant in the litigation.

Judge Sue L. Robinson signed off on the parties' consent order of dismissal in the U.S. District Court for the District of Delaware a day after a bench trial began.

Details of the agreement with the unit of Israel-based Teva Pharmaceutical Industries...
To view the full article, register now.